The Effect of Soursop Supplementation on Blood Pressure, Serum Uric Acid and Kidney Function in Prehypertensive Patients

Overview

This study was a randomized controlled trial study. The aim of this study was to determine the effect of soursop fruit supplementation on blood pressure (BP), serum uric acid (SUA), and kidney function. The definition of prehypertension and hypertension was accepted as delivered in The Seventh Report of the Joint National Committee (JNC 7) as the systolic BP was 120 – 139 mmHg and diastolic BP was 80 – 89 mmHg for prehypertension, while systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg for hypertension. Based on the study by Sja'bani (2014), the cut-off point of (SUA) was divided into 3 categories, which are normal (< 5 mg/dL), high-normal (5 – <7 mg/dL), and high (≥ 7 mg/dL). A number of 143 people with essential prehypertension and high normal uric acid level were assigned as subject in this study. Subjects were randomly assigned into two groups which are treatment and control group. For a 3 months period, the treatment group was given 2×100 g soursop fruit juice per day and the control group was left without treatment. Blood pressure was measured by medical team using Omron HEM-907 (digital automatic blood pressure monitoring) every 2 weeks (3 times readings for each) in each subject's home. Subjects were examined in sitting position. Evaluation of laboratory examination was taken at week 0, 7 and 13.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 12, 2018

Interventions

  • Dietary Supplement: Soursop supplementation
    • The soursop supplementation was given to treatment group (with soursop group) 2 times a day for 100 g each for 3 months period.
  • Other: Placebo
    • Control group (without soursop group) was left without treatment during study period

Arms, Groups and Cohorts

  • Experimental: With Soursop
    • Treatment group (with soursop group) was a group which receive soursop supplementation
  • Placebo Comparator: Without Soursop
    • Control group (without soursop group) was a group which do not receive any intervention (placebo)

Clinical Trial Outcome Measures

Primary Measures

  • Change in baseline morning home blood pressure at week 7 and 13
    • Time Frame: Week 0, 7 and 13
    • Blood pressure was measured by medical team using Omron HEM-907 (digital automatic blood pressure monitoring) every 2 weeks (3 times readings for each) in each subject’s home. Subjects were examined in sitting position.
  • Change in baseline serum uric acid at week 7 and 13
    • Time Frame: Week 0, 7 and 13
    • Blood sample was taken to measure serum uric acid level

Secondary Measures

  • Change in baseline CKD-Epi at week 7 and 13
    • Time Frame: Week 0, 7 and 13
    • Measurement of glomerular filtration rate
  • Change in baseline uric acid excretion at week 7 and 13
    • Time Frame: Week 0, 7 and 13
    • 24-h urine sample was taken to measure uric acid excretion

Participating in This Clinical Trial

Inclusion Criteria

1. pre-hypertensive patients in accordance with JNC 7 (Joint National Committee 7) criteria, 2. male or female resident in Mlati, Sleman with or without family history of hypertension, 3. age 30-59 years, 4. high normal uric acid levels (≥ 5 and < 7 mg/dL) and 5. agreed to follow the study by giving their informed consent. Exclusion Criteria:

1. have a history of diabetes, chronic renal failure, 2. using hormonal contraceptive, 3. in pregnancy, 4. taking uric acid-lowering drugs (allopurinol, probenecid), 5. positive urine reduction, positive proteinuria, creatinine > 1.5 g/dL, Blood Glucose > 126 g/dL.

Gender Eligibility: All

Minimum Age: 30 Years

Maximum Age: 59 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Gadjah Mada University
  • Collaborator
    • Mlati Study Group, Faculty of Medicine, Gadjah Mada University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Mochammad Sja’bani, Professor – Gadjah Mada University
  • Overall Official(s)
    • Mochammad Sja’bani, PhD, Principal Investigator, Department of Internal Medicine, Faculty of Medicine, University of Gadjah Mada

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.